Impaired nitric oxide modulation of myocardial oxygen consumption in genetically cardiomyopathic hamsters

J Mol Cell Cardiol. 2000 Dec;32(12):2299-306. doi: 10.1006/jmcc.2000.1258.

Abstract

We investigated the role of kinin and nitric oxide (NO) in the modulation of cardiac O(2)consumption in Syrian hamsters with overt heart failure (HF) and age-matched normal hamsters. Using echocardiography, the hamsters with heart failure had reduced ejection fraction [31(+/-8) v 76(+/-5)%] and LV dilation [4.9(+/-0. 2) v 5.7(+/-0.3) mm, both P<0.05 from normal]. O(2)consumption in the left ventricular free wall was measured using a Clark-type O(2)electrode in an air-tight chamber, containing Krebs solution buffered with Hepes (37 degrees C, pH 7.4). Concentration response curves to bradykinin (BK), ramiprilat (RAM), amlodipine (AMLO) and the NO donor, S -nitroso- N -acetyl-penicillamine (SNAP) were performed. Basal myocardial O(2)consumption was lower in the HF group compared to normal [316(+/-21) v 404(+/-36) nmol O(2)/min/g, respectively, P<0.05]. In the hearts from normal hamsters BK (10(-4)mol/l), RAM (10(-4)mol/l), and AMLO (10(-5)mol/l) all significantly reduced myocardial O(2)consumption by 42(+/-6)%, 29(+/-7)% and 27(+/-5)% respectively. This reduction was attenuated in the presence of N -nitro- l -arginine methyl ester (l -NAME) [BK: 3.3(+/-1.5)%, RAM: 3.3(+/-1.2)%, AMLO: 2.3(+/-1.2)%, P<0.05]. Interestingly in the hearts from HF group, BK, RAM and AMLO caused a significantly smaller reduction in myocardial O(2)consumption [10(+/-2)%, 2.5(+/-1.3)%, 6.3(+/-2.3)%, P<0.05]. In contrast, the NO donor SNAP reduced myocardial O(2)consumption in both groups and all those responses were not affected by l -NAME. These data indicate that endogenous NO production through the kinin-dependent mechanism is impaired at end-stage heart failure. The loss of kinin and NO control of mitochondrial respiration may contribute to the pathogenesis of heart failure.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amlodipine / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Animals
  • Body Weight / drug effects
  • Bradykinin / pharmacology
  • Cardiomyopathies / genetics*
  • Cardiomyopathies / metabolism*
  • Cricetinae
  • Dose-Response Relationship, Drug
  • Echocardiography
  • Enzyme Inhibitors / pharmacology
  • Kinins / physiology
  • Male
  • Mesocricetus
  • Muscles / metabolism
  • Myocardium / metabolism*
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide / physiology*
  • Nitric Oxide Donors / pharmacology
  • Organ Size / drug effects
  • Oxygen / metabolism
  • Oxygen Consumption* / drug effects
  • Penicillamine / analogs & derivatives*
  • Penicillamine / pharmacology
  • Ramipril / analogs & derivatives*
  • Ramipril / pharmacology
  • Vasodilator Agents / pharmacology

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Enzyme Inhibitors
  • Kinins
  • Nitric Oxide Donors
  • S-nitro-N-acetylpenicillamine
  • Vasodilator Agents
  • Amlodipine
  • Nitric Oxide
  • ramiprilat
  • Penicillamine
  • Ramipril
  • Oxygen
  • Bradykinin
  • NG-Nitroarginine Methyl Ester